
CAC2 Childhood Cancer Community News Digest (May 15-21)
Assorted News from the Last Week: About one-third of children and two-thirds of adults with relapsed or refractory neuroblastoma responded to single-agent lorlatinib. Bereaved parents
Assorted News from the Last Week: About one-third of children and two-thirds of adults with relapsed or refractory neuroblastoma responded to single-agent lorlatinib. Bereaved parents
Assorted News from the Last Week: Childhood cancer survivors have increased rates of late, major surgeries—Magnitude of the risk is “striking.” As the US faces
Assorted News from the Last Week: Analysis finds found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result
Assorted News from the Last Week: Adding a postinduction course of blinatumomab (Blincyto) to chemotherapy appeared safe and highly effective for treating an aggressive form
Assorted News from the Last Week: Children with acute lymphoblastic leukemia (ALL) who live in extreme poverty and were undergoing maintenance therapy faced an almost
Assorted News from the Last Week: Cancer researchers continue to make progress in developing tests using liquid biopsies for pediatric solid tumors that could complement
Assorted News from the Last Week: From the Journal of Clinical Oncology: “An optimized, agreed approach to the design and evaluation of early-phase pediatric combination trials
Assorted News from the Last Week: Melissa Jackson joins the Coalition Against Childhood Cancer as its new Executive Director. NCI Director Monica Bertagnolli announced the
Assorted News from the Last Week: Findings from a cohort study published in JAMA Network Open found that survivors of childhood cancer who lived in
Assorted News from the Last Week: Results from a new study show that giving a drug called dexrazoxane (Zinecard) before each dose of doxorubicin substantially